The study and prevention of blood diseases and cancer such as lymphoma and leukemia. The American Cancer Society projects that there will be nearly 600,000 US deaths from cancer in 2016 alone; the need for well-prepared and well-informed medical professionals has perhaps never been more pressing.

PARP in Practice: Expanding Options in the Maintenance Setting for Ovarian Cancer
CME: 1.0
Fungal Frontiers: Expert Decision Making in Medical Mycology
Define the role of emerging diagnostics in the management of invasive fungal disease (IFD)
CME: 2.0
Whiteboard Update: Transforming the Diagnosis and Treatment of Chronic Lymphocytic Leukemia
Develop individualized treatment plans for patients with CLL incorporating new agents based on genetic and molecular abnormalities, benefits and risks, comorbidities, and patient profiles
CME: 0.25
The Changing Landscape of Renal Cell and Bladder Cancers: Role of Immune Checkpoint Inhibitors
Examine the evidence for targeting the PD-1/PD-L1 pathway and CTLA-4 in immuno-oncology, including the use of checkpoint inhibitors
CME: 1.0
2018 Webinar: Controversies in Neoadjuvant Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer
Identify benefits of neoadjuvant therapy in patients with borderline resectable pancreatic cancer
CME: 1.0
Follicular Lymphoma: Best Practices in the Therapeutic Management
Assess optimal time to initiate treatment for FL in order to delay disease progression and maintain patient quality of life
CME: 1.0
Harnessing Immuno-Oncology for the Management of Genitourinary Cancers
Evaluate approaches to manage immune-related adverse effects associated with immune checkpoint inhibitors in patients with genitourinary cancer, including renal cell and bladder cancer.
CME: 1.0
Analysis of Recently Published Acute Lymphoblastic Leukemia Articles / Studies
Summarize the latest research developments in the treatment of acute lymphoblastic leukemia
CME: 1.25
Management of Pemphigus Vulgaris: Challenges and Solutions
Apply findings from trials of current and emerging therapies to select treatment for patients with pemphigus vulgaris.
CME: 1.0

Hematology/Oncology